Acute Myeloid Leukemia Clinical Trial
— VALOROfficial title:
Venetoclax AML Observational Real-World Study of Treatment-naïve Patients Ineligible for Intensive Chemotherapy in Switzerland & Austria
NCT number | NCT05215639 |
Other study ID # | P21-937 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 27, 2021 |
Est. completion date | November 14, 2023 |
Verified date | December 2023 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Switzerland & Austria. Venetoclax is a drug approved to treat acute myeloid leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled. Around 120 participants will be enrolled in the study in approximately 15 sites in Switzerland & Austria. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 24 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
Status | Completed |
Enrollment | 124 |
Est. completion date | November 14, 2023 |
Est. primary completion date | November 14, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Newly-diagnosed AML and eligible to receive venetoclax as per local label. - Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study. Exclusion Criteria: - Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation. |
Country | Name | City | State |
---|---|---|---|
Austria | Krankenhaus der Barmherzigen Brueder Graz /ID# 254121 | Graz | Steiermark |
Austria | Klinikum Klagenfurt am Woerthersee /ID# 247304 | Klagenfurt Am Woerthersee | Kaernten |
Austria | Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 254174 | Leoben | Steiermark |
Austria | Ordensklinikum Linz GmbH Elisabethinen /ID# 247284 | Linz | Oberoesterreich |
Austria | Universitaetsklinikum St. Poelten /ID# 247283 | Sankt Poelten | Niederoesterreich |
Austria | Klinik Ottakring /ID# 247285 | Vienna | Wien |
Austria | Hanusch Krankenhaus /ID# 247282 | Wien | |
Switzerland | Kantonsspital Aarau AG /ID# 251598 | Aarau | Aargau |
Switzerland | Kantonsspital Baden /ID# 241896 | Baden | Aargau |
Switzerland | Universitätsspital Basel /ID# 256509 | Basel | Basel-Stadt |
Switzerland | EOC Ospedale Regionale di Bellinzona e Valli /ID# 240663 | Bellinzona | Ticino |
Switzerland | Inselspital, Universitätsspital Bern /ID# 239241 | Bern | |
Switzerland | Spitalzentrum Oberwallis /ID# 241897 | Brig | |
Switzerland | Luzerner Kantonsspital /ID# 239242 | Luzern 16 | Luzern |
Switzerland | Hôpital de Nyon /ID# 240720 | Nyon | |
Switzerland | Hôpital du Chablais, Rennaz /ID# 241895 | Rennaz | |
Switzerland | Kantonsspital St. Gallen /ID# 239233 | St. Gallen | Sankt Gallen |
Switzerland | KSW Kantonsspital Winterthur /ID# 239852 | Winterthur | Zuerich |
Switzerland | Hirslanden Zürich /ID# 239239 | Zurich |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
Austria, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving Overall Survival (OS) | OS is defined as the time from treatment initiation to death from any cause. | Up to Month 24 | |
Secondary | Percentage of Participants Achieving Composite Complete Remission | Composite complete remission is defined as the proportion of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi). | Up to Month 24 | |
Secondary | Time to Transfusion Independence | Time to transfusion independence is defined as the time between the date of first venetoclax intake and the absence of any Red Blood Cell (RBC) or platelet transfusion during any consecutive 8 and/or 16 weeks during the treatment period and percentage of participants achieving transfusion independence. | Up to Month 24 | |
Secondary | Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Considered Minimally Clinical Important | The EQ-5D-5L is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments. | Up to Month 24 | |
Secondary | Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Considered Minimally Clinical Important | The EORTC QLQ-C30 is developed to assess the quality of life of cancer patients and is based on multi-item and single-item scales. The core questionnaire contains 5 functional scales, 3 symptom scales, 1 global health status scale, as well as 6 single-item measures. | Up to Month 24 | |
Secondary | Treatment Patterns Venetoclax in Combination with Hypomethylating Agents (HMAs) and in Switzerland in combination with Low Dose Cytarabine (LDAC) | Treatment patterns defined by the proportion of participants treated with venetoclax in combination with HMAs and in Switzerland in combination with LDAC. | Up to Month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |